5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

5-MeO-DMT is a tryptamine being developed as a potential antidepressant that may display a distinct therapeutic mechanism due to its unique pharmacology and subjective effects compared to typical psychedelics. In this article, we parallel the relatively distinct phenomenology and behavioral effects...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PSYCHOPHARMACOLOGY 2023-12, p.1
Hauptverfasser: Dourron, Haley Maria, Nichols, Charles D, Simonsson, Otto, Bradley, Melissa, Carhart-Harris, Robin, Hendricks, Peter S
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 1
container_title PSYCHOPHARMACOLOGY
container_volume
creator Dourron, Haley Maria
Nichols, Charles D
Simonsson, Otto
Bradley, Melissa
Carhart-Harris, Robin
Hendricks, Peter S
description 5-MeO-DMT is a tryptamine being developed as a potential antidepressant that may display a distinct therapeutic mechanism due to its unique pharmacology and subjective effects compared to typical psychedelics. In this article, we parallel the relatively distinct phenomenology and behavioral effects of the acute and post-acute effects of 5-MeO-DMT to those induced by epileptiform activity, particularly in instances within epileptogenic zones of the temporal lobes. This is done by reviewing aberrant 5-HT receptor functioning in epilepsy, noting that 5-MeO-DMT has notable 5-HT receptor agonist properties-and then comparing the acute behavioral and subjective effects induced by 5-MeO-DMT to those that occur in seizures. It might be that 5-MeO-DMT's therapeutic mechanism is partly mediated by evoking temporary epileptiform activity, suggesting a similarity to electroconvulsive therapy. It is also noted that "reactivations," the sudden re-experiencing of drug effects common after 5-MeO-DMT but not after typical psychedelics, may suggest that 5-MeO-DMT produces recurrent epileptiform activity. Overall, this review indicates that further evaluation of 5-MeO-DMT's unique mechanisms in research settings and among naturalistic users are warranted.
doi_str_mv 10.1007/s00213-023-06517-1
format Article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_837768</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2902937691</sourcerecordid><originalsourceid>FETCH-LOGICAL-c292t-cde408dfee29fdbdbc1b89f7c364caea9745d13ba8494797077b05b62890ce0a3</originalsourceid><addsrcrecordid>eNo9kE1LxDAQhoMouq7-AQ_Sk3gwOvlok3iRxW9YEUTPIU2nbrXd1maL7L83664GhsyEZ17IQ8gRg3MGoC4CAGeCAo-VpUxRtkVGTApOOSi-TUYAQlDBUr1H9kP4gHiklrtkT-gIaCVH5CWlT_hMb55eL5PJPHGLZVd5VyddWPoZFlhXPvmuFrNkmFdfAybdzPWN823dvi_P4oTztom1GpOTpK_C59UB2SldHfBwc4_J293t6_UDnT7fP15PptRzwxfUFyhBFyUiN2WRF7lnuTal8iKT3qEzSqYFE7nT0khlFCiVQ5pnXBvwCE6MCV3nhm_shtx2fdW4fmlbV9nN02fs0GqhVKYjf7rmu76NXwkL21TBY127ObZDsNwAN0JlhkWUr1HftyH0WP6HM7Ar93bt3kb39te9XS0db_KHvMHif-VPtvgBZJV_bQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2902937691</pqid></control><display><type>article</type><title>5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology &amp; risk?</title><source>SpringerLink Journals - AutoHoldings</source><creator>Dourron, Haley Maria ; Nichols, Charles D ; Simonsson, Otto ; Bradley, Melissa ; Carhart-Harris, Robin ; Hendricks, Peter S</creator><creatorcontrib>Dourron, Haley Maria ; Nichols, Charles D ; Simonsson, Otto ; Bradley, Melissa ; Carhart-Harris, Robin ; Hendricks, Peter S</creatorcontrib><description>5-MeO-DMT is a tryptamine being developed as a potential antidepressant that may display a distinct therapeutic mechanism due to its unique pharmacology and subjective effects compared to typical psychedelics. In this article, we parallel the relatively distinct phenomenology and behavioral effects of the acute and post-acute effects of 5-MeO-DMT to those induced by epileptiform activity, particularly in instances within epileptogenic zones of the temporal lobes. This is done by reviewing aberrant 5-HT receptor functioning in epilepsy, noting that 5-MeO-DMT has notable 5-HT receptor agonist properties-and then comparing the acute behavioral and subjective effects induced by 5-MeO-DMT to those that occur in seizures. It might be that 5-MeO-DMT's therapeutic mechanism is partly mediated by evoking temporary epileptiform activity, suggesting a similarity to electroconvulsive therapy. It is also noted that "reactivations," the sudden re-experiencing of drug effects common after 5-MeO-DMT but not after typical psychedelics, may suggest that 5-MeO-DMT produces recurrent epileptiform activity. Overall, this review indicates that further evaluation of 5-MeO-DMT's unique mechanisms in research settings and among naturalistic users are warranted.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-023-06517-1</identifier><identifier>PMID: 38072874</identifier><language>eng</language><publisher>Germany</publisher><ispartof>PSYCHOPHARMACOLOGY, 2023-12, p.1</ispartof><rights>2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c292t-cde408dfee29fdbdbc1b89f7c364caea9745d13ba8494797077b05b62890ce0a3</cites><orcidid>0000-0002-1589-4081</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38072874$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:154346361$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Dourron, Haley Maria</creatorcontrib><creatorcontrib>Nichols, Charles D</creatorcontrib><creatorcontrib>Simonsson, Otto</creatorcontrib><creatorcontrib>Bradley, Melissa</creatorcontrib><creatorcontrib>Carhart-Harris, Robin</creatorcontrib><creatorcontrib>Hendricks, Peter S</creatorcontrib><title>5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology &amp; risk?</title><title>PSYCHOPHARMACOLOGY</title><addtitle>Psychopharmacology (Berl)</addtitle><description>5-MeO-DMT is a tryptamine being developed as a potential antidepressant that may display a distinct therapeutic mechanism due to its unique pharmacology and subjective effects compared to typical psychedelics. In this article, we parallel the relatively distinct phenomenology and behavioral effects of the acute and post-acute effects of 5-MeO-DMT to those induced by epileptiform activity, particularly in instances within epileptogenic zones of the temporal lobes. This is done by reviewing aberrant 5-HT receptor functioning in epilepsy, noting that 5-MeO-DMT has notable 5-HT receptor agonist properties-and then comparing the acute behavioral and subjective effects induced by 5-MeO-DMT to those that occur in seizures. It might be that 5-MeO-DMT's therapeutic mechanism is partly mediated by evoking temporary epileptiform activity, suggesting a similarity to electroconvulsive therapy. It is also noted that "reactivations," the sudden re-experiencing of drug effects common after 5-MeO-DMT but not after typical psychedelics, may suggest that 5-MeO-DMT produces recurrent epileptiform activity. Overall, this review indicates that further evaluation of 5-MeO-DMT's unique mechanisms in research settings and among naturalistic users are warranted.</description><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNo9kE1LxDAQhoMouq7-AQ_Sk3gwOvlok3iRxW9YEUTPIU2nbrXd1maL7L83664GhsyEZ17IQ8gRg3MGoC4CAGeCAo-VpUxRtkVGTApOOSi-TUYAQlDBUr1H9kP4gHiklrtkT-gIaCVH5CWlT_hMb55eL5PJPHGLZVd5VyddWPoZFlhXPvmuFrNkmFdfAybdzPWN823dvi_P4oTztom1GpOTpK_C59UB2SldHfBwc4_J293t6_UDnT7fP15PptRzwxfUFyhBFyUiN2WRF7lnuTal8iKT3qEzSqYFE7nT0khlFCiVQ5pnXBvwCE6MCV3nhm_shtx2fdW4fmlbV9nN02fs0GqhVKYjf7rmu76NXwkL21TBY127ObZDsNwAN0JlhkWUr1HftyH0WP6HM7Ar93bt3kb39te9XS0db_KHvMHif-VPtvgBZJV_bQ</recordid><startdate>20231211</startdate><enddate>20231211</enddate><creator>Dourron, Haley Maria</creator><creator>Nichols, Charles D</creator><creator>Simonsson, Otto</creator><creator>Bradley, Melissa</creator><creator>Carhart-Harris, Robin</creator><creator>Hendricks, Peter S</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><orcidid>https://orcid.org/0000-0002-1589-4081</orcidid></search><sort><creationdate>20231211</creationdate><title>5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology &amp; risk?</title><author>Dourron, Haley Maria ; Nichols, Charles D ; Simonsson, Otto ; Bradley, Melissa ; Carhart-Harris, Robin ; Hendricks, Peter S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c292t-cde408dfee29fdbdbc1b89f7c364caea9745d13ba8494797077b05b62890ce0a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dourron, Haley Maria</creatorcontrib><creatorcontrib>Nichols, Charles D</creatorcontrib><creatorcontrib>Simonsson, Otto</creatorcontrib><creatorcontrib>Bradley, Melissa</creatorcontrib><creatorcontrib>Carhart-Harris, Robin</creatorcontrib><creatorcontrib>Hendricks, Peter S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>PSYCHOPHARMACOLOGY</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dourron, Haley Maria</au><au>Nichols, Charles D</au><au>Simonsson, Otto</au><au>Bradley, Melissa</au><au>Carhart-Harris, Robin</au><au>Hendricks, Peter S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology &amp; risk?</atitle><jtitle>PSYCHOPHARMACOLOGY</jtitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2023-12-11</date><risdate>2023</risdate><spage>1</spage><pages>1-</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><abstract>5-MeO-DMT is a tryptamine being developed as a potential antidepressant that may display a distinct therapeutic mechanism due to its unique pharmacology and subjective effects compared to typical psychedelics. In this article, we parallel the relatively distinct phenomenology and behavioral effects of the acute and post-acute effects of 5-MeO-DMT to those induced by epileptiform activity, particularly in instances within epileptogenic zones of the temporal lobes. This is done by reviewing aberrant 5-HT receptor functioning in epilepsy, noting that 5-MeO-DMT has notable 5-HT receptor agonist properties-and then comparing the acute behavioral and subjective effects induced by 5-MeO-DMT to those that occur in seizures. It might be that 5-MeO-DMT's therapeutic mechanism is partly mediated by evoking temporary epileptiform activity, suggesting a similarity to electroconvulsive therapy. It is also noted that "reactivations," the sudden re-experiencing of drug effects common after 5-MeO-DMT but not after typical psychedelics, may suggest that 5-MeO-DMT produces recurrent epileptiform activity. Overall, this review indicates that further evaluation of 5-MeO-DMT's unique mechanisms in research settings and among naturalistic users are warranted.</abstract><cop>Germany</cop><pmid>38072874</pmid><doi>10.1007/s00213-023-06517-1</doi><orcidid>https://orcid.org/0000-0002-1589-4081</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0033-3158
ispartof PSYCHOPHARMACOLOGY, 2023-12, p.1
issn 0033-3158
1432-2072
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_837768
source SpringerLink Journals - AutoHoldings
title 5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T17%3A29%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=5-MeO-DMT:%20An%20atypical%20psychedelic%20with%20unique%20pharmacology,%20phenomenology%20&%20risk?&rft.jtitle=PSYCHOPHARMACOLOGY&rft.au=Dourron,%20Haley%20Maria&rft.date=2023-12-11&rft.spage=1&rft.pages=1-&rft.issn=0033-3158&rft.eissn=1432-2072&rft_id=info:doi/10.1007/s00213-023-06517-1&rft_dat=%3Cproquest_swepu%3E2902937691%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2902937691&rft_id=info:pmid/38072874&rfr_iscdi=true